The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp. | Zendy

Laura Judith Marcos-Zambrano | Zendy; Marta GomezPerosanz | Zendy; Pilar Escribano | Zendy; Emilio Bouza | Zendy; Jesús Guinea | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.

Author(s) -

Laura Judith Marcos-Zambrano,

Marta GomezPerosanz,

Pilar Escribano,

Emilio Bouza,

Jesús Guinea

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx010

Subject(s) - micafungin , candida glabrata , candida parapsilosis , microbiology and biotechnology , fluconazole , candida albicans , candida tropicalis , biofilm , in vitro , echinocandins , biology , antifungal , biochemistry , bacteria , caspofungin , genetics

We studied the antifungal activity of SCY-078 (an orally bioavailable 1,3-β -d- glucan synthesis inhibitor), micafungin and fluconazole against the planktonic and sessile forms of 178 Candida and non- Candida isolates causing fungaemia in patients recently admitted to a large European hospital.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research